AIM ImmunoTech (AIM) Assets Average (2011 - 2026)
AIM ImmunoTech's (AIM) quarterly Assets Average came in at $7.2 million in Q1 2026, down 3.29% YoY from $7.4 million in Q1 2025, and up 27.41% on a QoQ basis from $5.6 million in Q4 2025.
AIM ImmunoTech (AIM) Assets Average (2011 - 2026) Analysis & Trends
AIM ImmunoTech (AIM) has 15 years of Assets Average data on file, last reported at $7.2 million in Q1 2026.
- Quarterly Assets Average fell 3.29% year-over-year to $7.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.2 million (down 3.29% YoY) and the FY2025 annual result came in at $7.2 million, down 48.59% from the prior year.
- Assets Average rose to $7.2 million in Q1 2026, from $5.6 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $55.9 million in Q1 2022 to a low of $4.8 million in Q3 2025.
- A 5-year average of $24.6 million and a median of $17.8 million in 2024 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2025 — Assets Average tumbled 67.47% — and 2026, when it slipped 3.29%.
- Tracing AIM's Assets Average over 5 years: stood at $43.4 million in 2022, then tumbled by 45.56% to $23.6 million in 2023, then tumbled by 53.02% to $11.1 million in 2024, then slumped by 49.2% to $5.6 million in 2025, then climbed by 27.41% to $7.2 million in 2026.
- The last three Assets Average figures came in at $7.2 million (Q1 2026), $5.6 million (Q4 2025), and $4.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | AIM ImmunoTech | 4.34 Mn | -5.62 Mn | 21,000.00 | 10.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.66 Mn |
| Mar 31, 2026 | 7.18 Mn |
| Dec 31, 2025 | 5.64 Mn |
| Sep 30, 2025 | 4.81 Mn |
| Jun 30, 2025 | 5.19 Mn |
| Mar 31, 2025 | 7.43 Mn |
| Dec 31, 2024 | 11.10 Mn |
| Sep 30, 2024 | 14.65 Mn |
| Jun 30, 2024 | 15.95 Mn |
| Mar 31, 2024 | 17.79 Mn |
| Dec 31, 2023 | 23.62 Mn |
| Sep 30, 2023 | 30.74 Mn |
| Jun 30, 2023 | 35.54 Mn |
| Mar 31, 2023 | 38.98 Mn |
| Dec 31, 2022 | 43.39 Mn |
| Sep 30, 2022 | 48.58 Mn |
| Jun 30, 2022 | 52.52 Mn |
| Mar 31, 2022 | 55.93 Mn |
| Dec 31, 2021 | 60.39 Mn |
| Sep 30, 2021 | 64.90 Mn |